Dermatological Disorders

PLIAGLIS (lidocaine/tetracaine) 7%/7% Cream

Pliaglis Approved for Topical Local Analgesia for Superficial Dermatological Procedures

Nuvo Research and Galderma Laboratories announced that the FDA has approved a supplemental New Drug Application (sNDA) for Pliaglis (lidocaine/tetracaine) 7%/7% Cream for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal).

Sequential Oral, Topical Tacrolimus Benefits Dermatitis

Filaggrin Mutations Up Risk of Irritant Contact Dermatitis

Both atopic dermatitis (AD) and loss-of-function mutations in the filaggrin gene (FLG) are independently associated with an increased risk of developing chronic irritant contact dermatitis (ICD), with people having both mutations at about a five-fold higher risk.

SORILUX (calcipotriene) 0.005% foam 60g aluminum can by Stiefel

Sorilux Foam Expands Plaque Psoriasis Indication

Stiefel, a GlaxoSmithKline company, announced that the FDA has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) foam, 0.005%. The expanded indication now includes the topical treatment of plaque psoriasis of the scalp in patients aged >18 years.

Choice of Psoriasis Treatment Affects CVD Event Rates

Choice of Psoriasis Treatment Affects CVD Event Rates

Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke.